

Hematology

Measure #4: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry

This measure may be used as an Accountability measure

Clinical Performance Measure

Numerator: t107238(r)322310i26

Definition: *Baseline flow cytometry studies: Refer to testing that is performed at time of diagnosis or prior to initiating treatment for that diagnosis. Treatment may include anti- neoplastic therapy.

Denominator: All patients aged 18 years and older, seen within a 12 month reporting period, with a diagnosis of chronic lymphocytic leukemia (CLL) made at any time during or prior to the reporting period

Denominator Exceptions:

Documentation of medical reason(s) for not performing baseline flow cytometry studies

Documentation of patient reason(s) for not performing baseline flow cytometry studies (eg, receiving palliative care or not receiving treatment as defined above)

Documentation of system reason(s) for not performing baseline flow cytometry studies (eg, patient previously treated by another physician at the time baseline flow cytometry studies were performed)

Measure Description: Percentage of patients aged 18 years and older, seen within a 12 month reporting period, with a diagnosis of chronic lymphocytic leukemia (CLL) made at any time during or prior to the reporting period who had baseline flow cytometry studies performed and documented in the chart

